+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Antipsychotics in the treatment of schizophrenia: an overview

Antipsychotics in the treatment of schizophrenia: an overview

Journal of Clinical Psychiatry 72(Suppl. 1): 4-8

Schizophrenia is characterized by positive, negative, cognitive, disorganization, and mood symptoms. Antipsychotics are the mainstay in the pharmacologic treatment of schizophrenia. Findings concerning efficacy for positive symptoms and disorganization suggest no consistent differences among available antipsychotics, with the exception of clozapine's superior efficacy for treatment-resistant schizophrenia. Efficacy for negative, depressive, and cognitive symptoms appears to be determined by (1) the extent to which reduction in positive symptoms brings about improvement in these other domains and (2) the extent to which extrapyramidal side effects (EPS) and anticholinergic effects (of the antipsychotic and of agents used to treat EPS) exacerbate them. Thus, the ability of antipsychotics to produce a potent antipsychotic effect without EPS and need for concomitant anticholinergic therapy yields multiple therapeutic benefits. In contrast to their broadly similar efficacy, antipsychotics differ markedly in their propensity to cause various adverse effects. Although second-generation antipsychotics (SGAs) have generally been believed to be associated with a lower risk of EPS but a higher risk of metabolic adverse effects than first-generation agents (FGAs), the substantial variation in these and other side effects among agents within both classes indicates that it is not clinically useful to make a categorical distinction between FGAs and SGAs. Choice of antipsychotic medication should be based on individual preference, prior treatment response and side effect experience, medical history and risk factors, and adherence history, with side effect profile a major determinant of antipsychotic choice.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 051592173

Download citation: RISBibTeXText

PMID: 22217436

DOI: 10.4088/jcp.10075su1.01

Related references

Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ 321(7273): 1371-1376, 2 December, 2000

Schizophrenia and antipsychotics associated with the metabolic syndrome. An overview. Tijdschrift Voor Psychiatrie 50(10): 645-654, 2008

Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The Schizophrenia Treatment & Assessment Group. Advances in Therapy 16(2): 78-88, 1999

Long-acting antipsychotics in the maintenance treatment of schizophrenia. Part II. Management of medications, integration of the multiprofessional team, and perspectives with the formulation of new a new generation of long-acting antipsychotics. Revista Latino-Americana de Enfermagem 11(4): 507-515, 2004

The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis. Systematic Reviews 3: 116, 2014

Traditional Chinese medical treatment to invigorate blood and relieve stasis treatment of schizophrenia: comparison with antipsychotics treatment. Psychiatry and Clinical Neurosciences 52 Suppl: S329-S330, 1998

Antipsychotics in the treatment of schizophrenia. Progress in Neurology and Psychiatry 17(3): 6-18, 2013

Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics. Psychiatry and Clinical Neurosciences 58(3): 268-273, 2004

Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Services 58(4): 482-488, 2007

Depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia. 2011

Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics. Psychiatrische Praxis 34(6): 289-291, 2007

Review: depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia. Evidence-Based Mental Health 14(4): 112-112, 2011

Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia?. Mini Reviews in Medicinal Chemistry 11(7): 565-574, 2011

FMRI, antipsychotics and schizophrenia. Influence of different antipsychotics on BOLD-signal. Current Pharmaceutical Design 16(18): 2012-2025, 2010